Chorein, the protein responsible for chorea-acanthocytosis, interacts with

β-adducin and β-actin

Nari Shiokawa, Masayuki Nakamura[*], Mieko Sameshima, Akiko Deguchi, Takehiro

Hayashi, Natsuki Sasaki, Akira Sano

Department of Psychiatry, Kagoshima University Graduate School of Medical and

Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan

*Corresponding author: Masayuki Nakamura, Department of Psychiatry, Kagoshima

University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka,

Kagoshima 890-8520, Japan.

Tel: +81-99-275-5346

Fax: +81-99-265-7089

E-mail: nakamu36@m.kufm.kagoshima-u.ac.jp

1

Abstract

Chorea-acanthocytosis (ChAc) is an autosomal, recessive hereditary disease characterized by striatal neurodegeneration and acanthocytosis, and caused by loss of function mutations in the vacuolar protein sorting 13 homolog A (*VPS13A*) gene. *VPS13A* encodes chorein whose physiological function at the molecular level is poorly understood. In this study, we show that chorein interacts with β-adducin and β-actin. We first compare protein expression in human erythrocyte membranes using proteomic analysis. Protein levels of β-adducin isoform 1 and β-actin are markedly decreased in erythrocyte membranes from a ChAc patient. Subsequent co-immunoprecipitation (co-IP) and reverse co-IP assays using extracts from chorein-overexpressing human embryonic kidney 293 (HEK293) cells, shows that β-adducin (isoforms 1 and 2) and β-actin interact with chorein. Immunocytochemical analysis using chorein-overexpressing HEK293 cells demonstrates co-localization of chorein with β-adducin and β-actin. In addition, immunoreactivity of β-adducin isoform 1 is significantly decreased in the striatum of gene-targeted ChAc-model mice. Adducin and actin are membrane cytoskeletal proteins, involved in synaptic function.

Expression of β-adducin is restricted to the brain and hematopoietic tissues,

corresponding to the main pathological lesions of ChAc, and thereby implicating

β-adducin and β-actin in ChAc pathogenesis.

Keywords: β-adducin, β-actin, chorein, chorea-acanthocytosis,

co-immunoprecipitation, *VPS13A*

Abbreviations: ChAc, chorea-acanthocytosis; *VPS13A*, vacuolar protein sorting 13

homolog A; HEK293, human embryonic kidney 293; TtVPS13A, *Tetrahymena*

thermophila VPS13A; MEME, Minimum Essential Medium Eagle; FBS, fetal bovine

serum; CBB, Coomassie Brilliant Blue; MALDI-TOF, matrix-assisted laser

desorption ionization-time of flight; PMF, peptide mass fingerprint; PBS-T, PBS

containing 0.1% Tween-20

1. Introduction

Chorea-acanthocytosis (ChAc; OMIM ID: 200150) is a rare, hereditary,

neurodegenerative disorder characterized by adult-onset chorea and acanthocytosis in

erythrocytes [1]. ChAc patients also develop psychiatric symptoms (including oral

self-mutilation), epilepsy, peripheral neuropathy, and myopathy [2, 3]. The main

neuropathological feature of ChAc is neurodegeneration of the striatum [4, 5]. Using

positional cloning, we and others, previously identified ChAc causative mutations in

the vacuolar protein sorting 13 homolog A (*VPS13A*) gene [6, 7], finding the

mutations widely distributed throughout the gene [8, 9]. *VPS13A* is located on human

chromosome 9q21, spanning an approximately 250-kb region, and encoding chorein, a

360-kDa protein [6]. The *Saccharomyces cerevisiae* homolog, *VPS13p*, is involved in

trafficking of membrane proteins from the trans-Golgi network to the prevacuolar

compartment [10], and an ortholog of *Vps13p*, the mutant *TipC* gene in *Dictyostelium*

discoideum, shows aberrant cell-sorting behavior [11]. In addition, the *Tetrahymena*

thermophila VPS13A (TtVPS13A) protein is required for phagocytosis [12], and in

PC12 cells, chorein is involved in dopamine release [13]. Altogether, these findings

suggest that chorein is involved in intracellular transport and vesicle-mediated sorting.

Chorein is highly expressed in mouse testis, kidney, spleen, and brain [14]. Subcellular

distribution studies indicate chorein is localized to the Golgi apparatus in the

microsomal fraction, and to dense-core vesicles in synaptosomes [13, 14]. Chorein is

also present in membrane fractions of erythrocytes [8, 9]. Abnormalities of erythrocyte

membrane proteins and the cytoskeleton are observed in ChAc patients [15, 16]. As

human autopsy tissue from ChAc patients is limited, we used gene targeting to develop

a mouse ChAc model that encodes the human disease mutation [17]. Chorein

functional deficiency led to acanthocytosis and apoptosis of mouse striatal neurons,

yet the physiological function of chorein at the molecular level is poorly understood.

In this study, we performed a comparative proteomic analysis of human erythrocyte

ghosts, erythrocytes that are devoid of cytoplasmic contents but maintain membrane

and cytoskeletal elements. Protein levels of β-adducin isoform 1 and β-actin were

markedly decreased in erythrocyte membranes from a ChAc patient. To investigate the

association between chorein, β-adducin, and β-actin, we established human embryonic

kidney 293 (HEK293) cells stably overexpressing chorein. Co-immunoprecipitation

(Co-IP) and reverse co-IP assays showed that β-adducin isoforms 1 and 2, and β-actin,

interact with chorein. Adducin and actin are both components of the erythrocyte

membrane skeleton and involved in synaptic function [18, 19]. Immunocytochemical

analysis using HEK293 cells was also performed to confirm the biochemical findings.

Immunoblot analysis of β-adducin using ChAc model mice was also performed.

2. Materials and methods

2.1. Human samples and preparation of human erythrocyte ghosts

Erythrocytes from a ChAc patient, a ChAc mutant carrier, and a healthy control were

used [2]. Genetic testing of the patient and mutant carrier identified a homozygous and

heterozygous nonsense mutation (c.3889C>T), respectively, in *VPS13A*. All

participants gave informed consent and the study was approved by the Institutional

Review Board of Kagoshima University. Erythrocyte ghost samples were prepared as

described previously [9].

2.2. Cell culture and generation of stably transfected cell lines

HEK293 cell lines, obtained from the Health Science Research Resources Bank (Osaka, Japan) were grown in Minimum Essential Medium Eagle (MEME) (Sigma, St. Louis, MO, USA) supplemented with 10% (v/v) fetal bovine serum (FBS) (Gibco, Carlsbad, CA, USA), 50 U/mL penicillin, and 50 μg/mL streptomycin (both Nacalai Tesque, Inc., Kyoto, Japan). Cells were grown in an incubator at 37°C with a humidified atmosphere of 5% CO_2.

To generate stable cell lines overexpressing chorein, HEK293 cells were transfected with pCMV6 vector, containing an ORF clone of *Homo sapiens VPS13A* (transcript variant A) with a Myc-DDK tag at the C-terminus and a neomycin selectable cassette (Origene, Rockville, MD, USA), using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). After selection with 500 mg/mL G418 (Nacalai Tesque, Inc.) for > 2 weeks, mono clones were selected by single-cell dilution and expansion. Chorein overexpression was confirmed by immunoblot analysis and immunofluorescence (data not shown).

2.3. ChAc model mice and mouse brain preparation

ChAc model mice encoding a human disease mutation with deletion of exons 60–61 in

VPS13A, were produced by gene targeting as previously described [17]. ChAc model

mice were backcrossed for at least 10 generations on a C57BL/6J background (CLEA

JAPAN, Tokyo, Japan).

Brain tissue was obtained from C57BL/6J wild-type (+/+) and ChAc model mice with

the homozygous deletion genotype (−/−), and prepared as described previously [14].

Triton X-100 (1%) soluble fractions were subjected to NuPAGE followed by

immunoblot analysis. This study was approved by the Committee on Animal

Experimentation of Kagoshima University (Japan) and carried out in accordance with

its guidelines.

2.4. Mass spectrometry and database analysis

Using erythrocyte ghosts from the ChAc patient, *VPS13A* mutant heterozygous carrier

and healthy control, two-dimensional polyacrylamide gel electrophoresis was

performed. First, isoelectric focusing using Immobiline DryStrips pH 3–10 non-linear,

13 cm (GE Healthcare, Little Chalfont, UK) was performed, followed by SDS (10–18%) polyacrylamide gradient gel (Bio Craft, Tokyo, Japan) electrophoresis. Gels were stained with 0.1% Coomassie Brilliant Blue (CBB) G-250, and samples for matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) analysis were excised. In-gel digestion of individual protein spots was performed using trypsin. Peptide solutions were desalted using ZipTip C18 columns (Millipore, Billerica, MA, USA), according to the manufacturer's protocol. The AXIMA-CFR Shimadzu model MALDI-TOF mass spectrometer (Shimadzu, Kyoto, Japan) was used for mass analysis, with α-cyano-4-hydroxycinnamic acid as the matrix. Database searches of peptide mass fingerprints (PMF) were performed using Mascot software (Matrix Science, http://www. matrixscience.com/).

2.5. Antibodies

Rabbit polyclonal anti-chorein [14], mouse monoclonal anti-β-actin (Sigma), and goat polyclonal anti-N-terminal-β-adducin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies were used as primary and immunoprecipitation antibodies.

Anti-rabbit IgG, horseradish peroxidase (HRP)-linked species-specific (GE

Healthcare), anti-mouse IgG, HRP-linked species-specific (GE Healthcare), anti-goat

IgG-HRP (Santa Cruz Biotechnology), Alexa-488-labeled anti-rabbit IgG,

Alexa-555-labeled anti-mouse IgG, and Alexa-555-labeled anti-goat IgG (all

Invitrogen) antibodies were used as secondary antibodies.

2.6. Immunoprecipitation (IP)

Co-IP and reverse co-IP assays were performed using the Pierce

Co-Immunoprecipitation or c-Myc-Tag IP/Co-IP Kits (Thermo Scientific, Rockford,

IL, USA). HEK293 cell lysates were solubilized using Nonidet P-40 at a final

concentration of 0.5%. Soluble fractions (200–600 μg) from cell lysates (Input) were

incubated overnight at 4°C with antibody-immobilized beads. Beads were then

centrifuged at $1,000 \times g$ for 1 min, and washed three times with PBS before elution.

Protein samples eluted by NuPAGE LDS Sample buffer (Invitrogen) were heated to

99°C for 5 min. Samples of input proteins and eluates were analyzed by immunoblot

analysis.

2.7. Immunoblot analysis

Protein samples were denatured by NuPAGE LDS Sample buffer (Invitrogen), separated on NuPAGE® 4–12% Bis-Tris gels (Invitrogen), and electrophoretically transferred to polyvinylidene difluoride membranes (GE Healthcare). Equal loading of protein was confirmed using the MemCode Reversible Protein Stain Kit (Thermo Scientific). Membranes were blocked for 1 h at room temperature with 5% non-fat dried milk in PBS containing 0.1% Tween-20 (PBS-T), and incubated overnight at 4°C with primary antibodies for each target protein in PBS-T milk. After rinsing in PBS-T, membranes were incubated with appropriate second antibodies for 1 h at room temperature. Proteins were visualized using ECL Plus Western Blotting Detection System or ECL Prime Western Blotting Detection Reagent (GE Healthcare) and images recorded by digital analyzer (Fujifilm LAS-1000; Fujifilm, Tokyo, Japan).

2.8. Statistics

Data are presented as mean ± 95% confidence interval (CI). Differences were

evaluated using unpaired Welch t-tests, with $p < 0.01$ considered statistically

significant.

2.9. Immunocytochemistry

Stable chorein-overexpressing or mock-transfected HEK293 cells were sparsely

plated onto poly-D-lysine-coated 18-mm glass cover slips and cultured in MEME

containing 10% FBS and 500 mg/mL G418 for approximately 20 h. Cells were fixed

for 15 min in 0.1 M phosphate buffer containing 4% (w/v) paraformaldehyde. Cells

were washed with PBS-Glycine (0.01 M glycine in PBS, pH 7.4) three times and then

permeabilized with PBS containing 0.1% (w/v) Triton X-100 for 5 min. Cells were

washed with PBS-Glycine three times and blocked for 1 h at room temperature with

10% (w/v) non-fat dried milk in PBS-T containing 6% (w/v) glycine. Cells were

incubated with primary antibodies overnight at 4°C. After washing with PBS-T, they

were incubated with secondary antibodies for 1 h at room temperature. Coverslips

were washed, mounted with Vectashield medium containing DAPI (Vector

Laboratories, Burlingame, CA, USA), and viewed with an LSM 700 confocal

microscope system (Carl Zeiss, Jena, Germany).

3. Results

3.1. Protein expression levels in erythrocyte ghosts from a ChAc patient

To identify erythrocyte proteins differentially expressed in ChAc, we performed a

comparative proteomic analysis of erythrocyte ghosts from a ChAc patient, *VPS13A*

mutant heterozygous carrier, and a healthy control. In total, 35 spots were picked and

identified by PMF analysis (data not shown). ACTB protein (β-actin) and adducin 2

isoform a (β-adducin isoform 1) showed lower expression levels in erythrocyte ghosts

from the ChAc patient than the control (Table 1).

3.2. β-adducin and β-actin interact with chorein

We generated HEK293 cells stably overexpressing Myc-DDK tagged chorein. To

examine the association between β-adducin and chorein, co-IP and reverse co-IP

assays were performed using anti-c-Myc and anti-β-adducin antibodies, respectively.

13

Bands of 97 kDa and approximately 60 kDa were co-immunoprecipitated with chorein

(Fig. 1A), corresponding to β-adducin isoform 1 and isoform 2, respectively. A

positive chorein signal was also observed in the β-adducin immunoprecipitate (Fig.

1B). IP controls using mock-transfected HEK293 cells failed to precipitate either

protein (Fig. 1A, B). These results indicate that overexpressed chorein interacts with

β-adducin in HEK293 cells.

To examine the association between β-actin and chorein, co-IP and reverse co-IP

assays using anti-c-Myc and anti-β-actin antibodies, respectively, were also performed.

A strong positive β-actin signal was observed in the chorein immunoprecipitate (Fig.

2A), and similarly, a chorein positive signal was observed in the β-actin

immunoprecipitate (Fig. 2B), suggesting that overexpressed chorein interacts with

β-actin.

3.3. Co-localization of chorein with β-adducin and β-actin

Our biochemical findings show that β-adducin and β-actin interact with chorein. Next,

we used immunocytochemistry to determine if these proteins co-localize with chorein

in chorein-overexpressing HEK293 cells (Fig. 3). Using an anti-chorein antibody,

chorein displayed a vesicular staining pattern that strongly co-localized with

β-adducin (Fig. 3A), and partially co-localized with β-actin (Fig. 3B).

3.4. Comparison of β-adducin and β-actin immunoreactivity in the brain of ChAc

model mice

We analyzed 1% Triton X-100-soluble fractions of brain regions from wild-type

(+/+) and ChAc model (−/−) mice by immunoblotting using an anti-β-adducin

antibody. In mouse brain, the β-adducin isoform 1 was observed, but isoform 2 was not

detected in any brain regions. Immunoreactivity of β-adducin was significantly lower

in the striatum of ChAc model mice, but no significant differences were detected in the

cerebral cortex or hippocampus (Fig. 4). There was no significant difference in β-actin

immunoreactivity in any brain regions (data not shown).

4. Discussion

This study is the first biochemical demonstration of chorein interacting proteins.

Chorein is thought to be involved in intracellular trafficking and vesicle-mediated

sorting [10, 11, 12]. However, its physiological function at the molecular level, and

interacting partners, are unclear. In this study, we performed proteomic analysis, co-IP,

reverse co-IP, and immunocytochemical analyses, revealing that β-adducin and

β-actin are chorein interacting partners.

Adducin in humans and rodents includes three subunits: α, β, and γ. All three adducin

subunits contain an N-terminal globular head domain, a neck domain, and a

C-terminal tail domain that has myristoylated alanine-rich C kinase substrate

(MARCKS)-related domains with clusters of lysine residues [20]. Although α- and

γ-adducin are expressed widely in tissues, β-adducin expression is restricted to the

brain and hematopoietic tissues [21], corresponding to the main pathological lesions of

ChAc. Adducin is an actin capping protein that binds to the barbed end of filamentous

(F-) actin to prevent further elongation and depolymerization [20, 22]. Adducin

promotes the association of spectrin with F-actin in erythrocyte membrane skeletons.

Adducin is expressed in the brain at high levels and is a component of synaptic

structures, such as dendritic spines and neuron growth cones, and subsequently, is

involved in the dynamic assembly-disassembly of the actin cytoskeleton during

synaptic plasticity [18]. In addition, β-adducin binds to rabphilin-3A, a protein

involved in synaptic vesicle trafficking [23, 24]. Moreover, β-adducin gene-deficient

mice show long-term synaptic plasticity, behavioral, motor coordination, and learning

deficits [18]. We found a decreased protein level and immunoreactivity of β-adducin in

erythrocyte membranes from a ChAc patient, and in the striatum of ChAc model mice,

suggesting β-adducin may be involved in ChAc molecular pathology.

Actin is a ubiquitous, essential cytoskeletal protein. The actin cytoskeleton is required

for modulation of the synaptic vesicle release cycle via multiple mechanisms [19, 25,

26]. F-actin indirectly binds to gephyrin, a $GABA_A$ receptor-anchoring protein that

shows enhanced expression in the striatum and hippocampus of ChAc model mice [27,

28]. Recent investigations found actin depolymerization induced in erythrocytes and

platelets from ChAc patients [29, 30]. As β-actin is an abundant housekeeping protein,

we were unable to detect any differences in β-actin immunoreactivity, although a

subtle difference may exist.

We found chorein exhibited a vesicular pattern of staining in HEK293 cells, similar to other vacuolar protein sorting (VPS) proteins [31, 32]. Human VPS52, 53, and 54 co-localize with the Golgi marker, GM130, and late endosome marker, mannose-6-phosphate-receptor [31], and human VPS11, 16, and 18 co-localize with the late endosome/lysosome marker, Lamp-1 [32]. Recently, chorein and COH1 (VPS13B) were also reported to co-localize with GM130 [13, 33]. Thus, chorein is likely to be associated with the Golgi apparatus and endosomes/lysosomes. Chorein-positive enlarged vesicular structures showed co-localization with β-adducin and partially co-localized with β-actin in HEK293 cells. Therefore, chorein may co-localize with its interacting proteins, β-adducin and β-actin, in neuronal cells to regulate the synaptic vesicle release cycle.

The actin-capping activity of β-adducin requires both the neck (amino acids 335–436) and C-terminal MARCKS-related (amino acids 700–726) domains, and can be inhibited by protein kinase A (PKA) and C (PKC) phosphorylation, and calmodulin [18, 34]. However, in this study, a β-adducin alternative product, predicted to be β-adducin isoform 2 (559 amino acids) that does not contain the highly basic carboxy

terminus of isoform 1, was also co-immunoprecipitated with chorein. The β-adducin

isoform 2 may have novel functions in ChAc pathology.

Human chorein contains a chorein_N motif, a proposed leucine zipper, a DUF1162

motif (conserved within vacuolar protein sorting-related proteins), and an ATG_C

motif that may function by targeting it to vacuoles. Chorein also contains 10 Tetratrico

Peptide Repeat motifs (Swiss-Prot entry Q96RL7) that potentially interact with other

binding partners, and is predicted to have a coiled-coil structure by the online program

PSORT II [13, 35]. However, chorein does not contain an actin-binding domain. The

actin and adducin binding sites in chorein remain unknown, and may not bind directly

to chorein.

Although further analyses are required, this study demonstrates that β-adducin and

β-actin are chorein-interacting proteins and may be involved in brain pathology and

acanthocytosis in ChAc. Our findings provide a basis for the development of

investigation into chorein functions and the molecular pathogenesis of ChAc.

Acknowledgments

References

[1] L. Rampoldi, A. Danek, A.P. Monaco, Clinical features and molecular bases of neuroacanthocytosis, J. Mol. Med. 80 (2002) 475–491.

[2] M. Ichiba, M. Nakamura, A. Kusumoto, et al., Clinical and molecular genetic assessment of a chorea-acanthocytosis pedigree, J. Neurol. Sci. 263 (2007) 124–132.

[3] R.H. Walker, Q. Liu, M. Ichiba, et al., Self-mutilation in chorea-acanthocytosis: Manifestation of movement disorder or psychopathology? Mov. Disord. 21 (2006) 2268–2269.

[4] A. Danek, H.H. Jung, M.A. Melone, et al., Neuroacanthocytosis: new developments in a neglected group of dementing disorders, J. Neurol. Sci. 229–230 (2005) 171–186.

[5] Y. Miki, M. Nishie, M. Ichiba, et al., Chorea-acanthocytosis with upper motor neuron degeneration and 3419_3420 delCA and 3970_3973 delAGTC *VPS13A* mutations, Acta. Neuropathol. 119 (2010) 271–273.

[6] S. Ueno, Y. Maruki, M. Nakamura, et al., The gene encoding a newly discovered protein, chorein, is mutated in chorea-acanthocytosis, Nat. Genet. 28 (2001) 121–122.

[7] L. Rampoldi, C. Dobson-Stone, J.P. Rubio, et al., A conserved sorting-associated protein is mutant in chorea-acanthocytosis, Nat. Genet. 28 (2001) 119–120.

[8] C. Dobson-Stone, A. Velayos-Baeza, L.A. Filippone, et al., Chorein detection for the diagnosis of chorea-acanthocytosis, Ann. Neurol. 56 (2004) 299–302.

[9] A. Tomiyasu, M. Nakamura, M. Ichiba, et al., Novel pathogenic mutations and copy number variations in the *VPS13A* gene in patients with chorea-acanthocytosis, Am. J. Med. Genet. B. Neuropsychiatr. Genet. 156B (2011) 620–631.

[10] J.H. Brickner, R.S. Fuller, *SOI1* encodes a novel, conserved protein that promotes TGN-endosomal cycling of Kex2p and other membrane proteins by modulating the function of two TGN localization signals, J. Cell. Biol. 139 (1997) 23–36.

[11] J.T. Stege, M.T. Laub, W.F. Loomis, *tip* genes act in parallel pathways of early Dictyostelium development, Dev. Genet. 25 (1999) 64–77.

[12] H.S. Samaranayake, A.E. Cowan, L.A. Klobutcher, Vacuolar protein sorting protein 13A, TtVPS13A, localizes to the *tetrahymena thermophila* phagosome membrane and is required for efficient phagocytosis, Eukaryot. Cell 10 (2011) 1207–1218.

[13] T. Hayashi, M. Kishida, Y. Nishizawa, et al., Subcellular localization and putative

role of VPS13A/chorein in dopaminergic neuronal cells, Biochem. Biophys. Res.

Commun. 419 (2012) 511–516.

[14] Y. Kurano, M. Nakamura, M. Ichiba, et al., In vivo distribution and localization of

chorein, Biochem. Biophys. Res. Commun. 353 (2007) 431–435.

[15] R. Prohaska, O.C. Sibon, D.D. Rudnicki, et al., Brain, blood, and iron: perspectives

on the roles of erythrocytes and iron in neurodegeneration, Neurobiol. Dis. 46 (2012)

607–624.

[16] L. De Franceschi, C. Tomelleri, A. Matte, et al., Erythrocyte membrane changes of

chorea-acanthocytosis are the result of altered Lyn kinase activity, Blood 118 (2011)

5652–5663.

[17] Y. Tomemori, M. Ichiba, A. Kusumoto, et al., A gene-targeted mouse model for

chorea-acanthocytosis, J. Neurochem. 92 (2005) 759–766.

[18] F. Porro, M. Rosato-Siri, E. Leone, et al., β-adducin (Add2) KO mice show synaptic

plasticity, motor coordination and behavioral deficits accompanied by changes in the

expression and phosphorylation levels of the α- and γ-adducin subunits, Genes. Brain.

Behav. 9 (2010) 84–96.

[19] S. Bellani, V.L. Sousa, G. Ronzitti, et al., The regulation of synaptic function by

α-synuclein, Commun. Integr. Biol. 3 (2010) 106–109.

[20] Y. Matsuoka, X. Li, V. Bennett, Adducin: structure, function and regulation, Cell.

Mol. Life. Sci. 57 (2000) 884–895.

[21] V. Bennett, A.J. Baines, Spectrin and ankyrin-based pathways: metazoan inventions

for integrating cells into tissues, Physiol. Rev. 81 (2001) 1353–1392.

[22] P.A. Kuhlman, C.A. Hughes, V. Bennett, et al., A new function for adducin:

calcium/calmodulin-regulated capping of the barbed ends of actin filaments, J. Biol.

Chem. 271 (1996) 7986–7991.

[23] M. Miyazaki, H. Shirataki, H. Kohno, et al., Identification as β-adducin of a protein

interacting with rabphilin-3A in the presence of Ca^{2+} and phosphatidylserine, Biochem.

Biophys. Res. Commun. 205 (1994) 460–466.

[24] M.E. Burns, T. Sasaki, Y. Takai, et al., Rabphilin-3A: a multifunctional regulator of

synaptic vesicle traffic, J. Gen. Physiol. 111 (1998) 243–255.

[25] G. Eitzen, Actin remodeling to facilitate membrane fusion, Biochem. Biophys. Acta.

1641 (2003) 175–181.

[26] M. Malacombe, M.F. Bader, S. Gasman, Exocytosis in neuroendocrine cells: new

tasks for actin, Biochim. Biophys. Acta. 1763 (2006) 1175–1183.

[27] M. Bausen, J.C. Fuhrmann, H. Betz, et al., The state of the actin cytoskeleton

determines its association with gephyrin: role of ena/VASP family members, Mol.

Cell. Neurosci. 31 (2006) 376–386.

[28] Y. Kurano, M. Nakamura, M. Ichiba, et al., Chorein deficiency leads to upregulation

of gephyrin and $GABA_A$ receptor, Biochem. Biophys. Res. Commun. 351 (2006)

438–442.

[29] M. Foller, A. Hermann, S. Gu, et al., Chorein-sensitive polymerization of cortical

actin and suicidal cell death in chorea-acanthocytosis, FASEB. J. 26 (2012)

1526–1534.

[30] E.M. Schmidt, E. Schmid, P. Munzer, et al., Chorein sensitivity of cytoskeletal

organization and degranulation of platelets, FASEB. J. 27 (2013) 2799–2806.

[31] H. Liewen, I. Meinhold-Heerlein, V. Oliveira, et al., Characterization of the human

GARP (Golgi associated retrograde protein) complex, Exp. Cell. Res. 306 (2005)

24–34.

[32] B.Y. Kim, H. Kramer, A. Yamamoto, et al., Molecular characterization of

mammalian homologues of class C Vps proteins that interact with syntaxin-7, J. Biol.

Chem. 276 (2001) 29393–29402.

[33] W. Seifert, J. Kuhnisch, T. Maritzen, et al., Cohen syndrome-associated protein,

COH1, is a novel, giant Golgi matrix protein required for Golgi integrity, J. Biol.

Chem. 286 (2011) 37665–37675.

[34] X. Li, Y. Matsuoka, V. Bennett, Adducin preferentially recruits spectrin to the fast

growing ends of actin filaments in a complex requiring the MARCKS-related domain

and a newly defined oligomerization domain, J. Biol. Chem. 273 (1998)

19329–19338.

[35] E. Mizuno, M. Nakamura, A. Agemura, et al., Brain-specific transcript variants of 5′

and 3′ ends of mouse *VPS13A* and *VPS13C*, Biochem. Biophys. Res. Commun. 353

(2007) 902–907.

Figure legends

Fig. 1. Chorein co-immunoprecipitates with β-adducin. (A) Co-immunoprecipitation (IP) assay using human embryonic kidney 293 (HEK293) cells stably overexpressing Myc-DDK tagged chorein was performed with anti-cMyc antibody. Immunoblot (IB) analyses used anti-chorein and anti-β-adducin antibodies. The β-adducin isoform 1 (97 kDa) and an alternative product (approximately 60 kDa) were co-immunoprecipitated with chorein. Co-IP using mock-transfected HEK293 cells with an anti-cMyc antibody was performed as a negative control. (B) Reverse co-IP assay confirmed an interaction between β-adducin and chorein. Immunoblot analyses used anti-chorein and anti-β-adducin antibodies.

Fig. 2. Chorein co-immunoprecipitates with β-actin. (A) Co-IP assay using human embryonic kidney 293 (HEK293) cells stably overexpressing Myc-DDK tagged chorein. Immunoblot analyses used anti-chorein and anti-β-actin antibodies. (B) Reverse co-IP assay using chorein-overexpressing HEK293 cell lysates. Immunoblot analyses used anti-chorein and anti-β-actin antibodies.

Fig. 3. Chorein partially co-localizes with β-adducin and β-actin in human embryonic kidney 293 (HEK293) cells stably overexpressing chorein. HEK293 cells stably overexpressing chorein were stained with anti-chorein (green) and anti-β-adducin (red) (A) or anti-β-actin (red) (B) antibodies. Cell nuclei were visualized using DAPI staining. Scale bars, 10 μm.

Fig. 4. Protein levels of β-adducin in mouse brain. (A) Six independent immunoblot results were shown. Immunoblot analysis of β-adducin in 1% Triton X-100-soluble fractions of the hippocampus, striatum, and cerebral cortex from wild-type (+/+) and ChAc model (−/−) mice. Bands of 97 kDa corresponding to β-adducin isoform 1 were shown. Decreased β-adducin isoform 1 immunoreactivity is observed in the striatum of −/− mice. No differences in band densities between +/+ and −/− mice were detected in the hippocampus or cerebral cortex. Identical gels were run and stained with Coomassie dye to confirm uniform protein loading. (B) Histograms showing

β-adducin isoform 1 relative density ratio in −/− to +/+ mice. Error bars represent 95%

confidence intervals (n = 6). ** $p < 0.01$.

29

Table

Table 1

Mascot search results. Comparison of β-actin and β-adducin protein levels in erythrocyte ghosts.

Spot #	GI number	Mass (Da)	Mascot score	Protein name	Norm Qty		
					Patient[a]	Hetero[b]	Control[c]
SSP 2602	15277503	40536	162	ACTB protein (beta-actin)	2488.2	3403.9	5731.7
SSP 2805	9257192	81260	101	Adducin 2 isoform a (beta-adducin isoform 1)	6.8	828.6	1362.3

[a]Patient: ChAc patient, *VPS13A* homozygous c.3889C>T.

[b]Hetero: ChAc mutant carrier, *VPS13A* heterozygous c.3889C>T.

[c]Control: healthy control.

Figure

Figure

A

Input	IP: anti-cMyc

−　　+　　　−　　+　　　chorein-cMyc-DDK

IB: Chorein

IB: β-actin

B

Input	IP: anti-β-actin

−　　+　　　−　　+　　　chorein-cMyc-DDK

IB: Chorein

IB: β-actin

Figure

A

DAPI   Chorein   β-adducin   Merge

B

DAPI   Chorein   β-actin   Merge

Figure

A

B